{"podcast":{"title":"Charged Alpha Stock Encyclopedia","slug":"charged-alpha-stock-encyclopedia-7819792","podcast_index_feed_id":7819792,"rss_url":"https://feed.podbean.com/chargedalpha/feed.xml","website_url":"https://chargedalpha.podbean.com","image_url":"https://pbcdn1.podbean.com/imglogo/image-logo/22241603/charged_alpha_logo_2048.png","author":"Colton Thomas","episode_count":1034,"summary":"Charged Alpha reviews earnings for each stock in the Russel 1000 every quarter. Each podcast gives thorough analysis, along with an in-depth profile in the beginning of the episode of the company, what they do, how they earn money and what to look for.","last_synced_at":"2026-07-18T10:20:29.083898+00:00","page_url":"https://stenobird.com/podcast/charged-alpha-stock-encyclopedia-7819792"},"episode":{"title":"JNJ Stock: A $100 Billion Milestone — But Is the Fortress Fully Priced?","slug":"jnj-stock-a-100-billion-milestone-but-is-the-fortress-fully-priced","published_at":"2026-07-16T23:16:06+00:00","page_url":"https://stenobird.com/podcast/charged-alpha-stock-encyclopedia-7819792/jnj-stock-a-100-billion-milestone-but-is-the-fortress-fully-priced","show_page_url":"https://stenobird.com/podcast/charged-alpha-stock-encyclopedia-7819792","url":"https://chargedalpha.podbean.com/e/jnj-stock-a-100-billion-milestone-%e2%80%94-but-is-the-fortress-fully-priced/","audio_url":"https://mcdn.podbean.com/mf/web/s5dxly00rdgjr0ai/audio_v.mp3","summary":"Johnson & Johnson (JNJ) Q2 2026 — Johnson & Johnson (JNJ) reported a clean Q2 2026 beat: sales +6.6% to $25.3B, adjusted EPS $2.90 (+4.7%, ahead of estimates), with Innovative Medicine (pharma) sales +6.8% out-growing the patent cliffs. It RAISED full-year guidance to ~$101.1B sales (+7.3%) and $11.68 adjusted EPS (+8.2%) — on track to cross $100B in annual revenue for the first time in its 140-year history. The AAA-rated Dividend King (~250) has recovered strongly off its ~$162 low to ~7% below its ~$269 high, and rose on the print. Johnson & Johnson is the ultimate healthcare fortress — a diversified, AAA-rated giant (one of only a handful on earth) with two engines (Innovative Medicine pharma + MedTech devices) and a 60+ year dividend-increase streak. In Q2 2026 it beat (sales +6.6% to $25.3B, adjusted EPS $2.90) and RAISED guidance to ~$101.1B sales and $11.68 adjusted EPS — crossing $100B in annual revenue for the first time in 140 years. The pharma engine (+6.8%) is out-growing the Stelara-style patent cliffs, which is the whole long-term debate. The overhangs are talc litigation and drug-pricing policy, and after recovering near its highs it trades at ~21x forward for ~8% growth — full, not cheap. Our owner-earnings work lands near $260 (vs ~$250), below the Street's ~$272. Our call: HOLD, 3/5 — a beat-and-raise from a fortress at a fair price; own it for resilience and the ~3% AAA-backed dividend, add on talc-driven dips. Not financial advice. THE CALL: HOLD (3/5, A HEALTHCARE FORTRESS, BEAT AND RAISED, AT A FAIR PRICE) — base-case value ~$260 vs ~$250 today. What to watch: a clean, capped talc-litigation settlement (removing the biggest overhang), continued pharma-pipeline launches out-growing the Stelara patent cliff, and talc-headline dips toward…","meta_description":"Johnson & Johnson (JNJ) Q2 2026 — Johnson & Johnson (JNJ) reported a clean Q2 2026 beat: sales +6.6% to $25.3B, adjusted EPS $2.90 (+4.7%, ahead o…","key_points":[],"chapters":[],"topics":[],"duration_seconds":797,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/charged-alpha-stock-encyclopedia-7819792/episodes/jnj-stock-a-100-billion-milestone-but-is-the-fortress-fully-priced/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/charged-alpha-stock-encyclopedia-7819792/jnj-stock-a-100-billion-milestone-but-is-the-fortress-fully-priced.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}